Shanghai Fosun Pharmaceutical (02196) has granted 10,589,500 restricted shares of H shares.

Shanghai Fosun Pharmaceutical (02196) announced that 6 of the initial grant recipients under the 2025 H-share restricted share unit plan are no longer employed by the group and are no longer eligible employees. In accordance with shareholder authorization, the Board of Directors approved adjustments to the list of initial grant recipients and the number of H-share restricted share units involved: the number of initial grant recipients was adjusted from 201 to 195, and the number of H-share restricted share units involved in the initial grant was adjusted from 10.6964 million to 10.5895 million. On November 4, 2025, the Board of Directors granted 10.5895 million H-share restricted share units.